We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Fig 2.

Fig 2. From: Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial.

(A) Percentage incidence of aggregate tumor regression in response to gemcitabine, albumin-bound (nab) paclitaxel, and gemcitabine plus nab-paclitaxel in individual xenografts derived from the 11 parental cases. (B) Immunohistochemical assay for collagen type 1 fibers in a gemcitabine-resistant human pancreatic cancer xenograft treated with nab-paclitaxel, gemcitabine, or gemcitabine plus nab-paclitaxel. (C) Intratumor concentration of gemcitabine in human pancreatic cancer xenografts.

Daniel D. Von Hoff, et al. J Clin Oncol. 2011 December 1;29(34):4548-4554.
2.
Fig 1.

Fig 1. From: Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial.

(A) Median overall survival in patients receiving 125 mg/m2 of albumin-bound (nab) paclitaxel followed by 1,000 mg/m2 of gemcitabine. (B) Median overall survival correlated with a complete metabolic response compared with baseline, defined according to the European Organisation for Research and Treatment of Cancer criteria by the absence of [18F]fluorodeoxyglucose uptake (cohorts 1 and 2). (C) Median survival correlated with secreted protein acidic and rich in cysteine (SPARC; all cohorts). (D) Maximum percentage change in CA19-9 levels in patients receiving 125 mg/m2 of nab-paclitaxel followed by 1,000 mg/m2 of gemcitabine. PR, partial response; SD, stable disease.

Daniel D. Von Hoff, et al. J Clin Oncol. 2011 December 1;29(34):4548-4554.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk